Login to Your Account



Pharma Focus

Lilly Reloads Solanezumab, Shoots for Mild Alzheimer's

By Marie Powers
Staff Writer

Monday, July 15, 2013
As promised, Eli Lilly and Co. is making another run at Alzheimer's disease (AD) with its Phase III candidate solanezumab (sola), this time in the mild form of the disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription